Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 6/2020

01-12-2020 | Obesity | Research Article

Opportunistic screening of cardiovascular disease risk factors in community pharmacies in Nigeria: a cross-sectional study

Authors: Casmir Amadi, Folasade Lawal, Wale Ajiboye, Rosarii Agbim, Amam Mbakwem, Jayne Ajuluchukwu, David A. Oke

Published in: International Journal of Clinical Pharmacy | Issue 6/2020

Login to get access

Abstract

Background Early identification and treatment of cardiovascular disease (CVD) risk factors through screening are crucial in the primary prevention of CVD and reduction in healthcare-related costs. Use of Non-Physician Healthcare-workers including Community Pharmacists has been advocated as an effective and cost-efficient model of healthcare delivery. In Nigeria the use of community pharmacists for mass screening of CVD risk factors has not been explored. Objective We sought to investigate the possibility of mass CVD risk factor screening in community pharmacies by pharmacists. Setting Lagos, Nigeria. Methods Between October and December 2018 eight hundred and eighty-nine apparently healthy participants were screened for obesity, hypertension, diabetes and hypercholesterolaemia in ten community pharmacies. Diabetes and hypercholesterolaemia were screened for using point-of-care testing modalities. A structured questionnaire was used to obtain the socio-demographic data of the participants. Main outcome measures Prevalence of overweight/obesity, hypertension, diabetes, hypercholesterolaemia, smoking and alcohol intake. Results Mean age of the subjects was 56.8 ± 21.1 years. Majority (57.4%) were females. Prevalence of smoking and alcohol intake were 4.3% and 26.7% respectively. 59.7% and 71.5% of males and females were either overweight (BMI ≥ 25 kg/m2) or obese (BMI ≥ 30 kg/m2) respectively. Prevalence of hypertension was 28.2% in all subjects, 30.9% in males and 26.3% in females, p < 0.001. Using BP > 130/80 mmHg prevalence of hypertension was 55.1%. Diabetes was detected in 3% of the subjects while 45.3% had hypercholesterolaemia. In total, 64.1% of the subjects were diagnosed with CVD risk factors for the first time. Conclusion Opportunistic screening for CVD risk factors is possible in community pharmacies and has the ability to detect previously undiagnosed risk factors. This community pharmacy based model could serve as a cost-effective approach to primary prevention of CVD.
Literature
1.
go back to reference World Health Organization. Prevention of cardiovascular disease: guidelines for assessment and management of cardiovascular risk. Geneva: World Health Organization; 2007. World Health Organization. Prevention of cardiovascular disease: guidelines for assessment and management of cardiovascular risk. Geneva: World Health Organization; 2007.
2.
go back to reference Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006;367(9524):1747–57. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006;367(9524):1747–57.
3.
go back to reference Bygbjerg IC. Double burden of non-communicable and infectious diseases in developing countries. Science. 2012;337(6101):1499–501. Bygbjerg IC. Double burden of non-communicable and infectious diseases in developing countries. Science. 2012;337(6101):1499–501.
4.
go back to reference O’Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, Rangarajan S, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet. 2010;376:112–23. O’Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, Rangarajan S, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet. 2010;376:112–23.
5.
go back to reference Yusuf S, Hawken S, Ounpuu S, Dans T, Avzum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937–52. Yusuf S, Hawken S, Ounpuu S, Dans T, Avzum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937–52.
6.
go back to reference Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001;104:2746–53. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001;104:2746–53.
7.
go back to reference Ferdinand KC, Patterson KP, Taylor C, Fergus IV, Nasser SA. Community-based approaches to prevention and management of hypertension and cardiovascular disease. J Clin Hypertens (Greenwich). 2012;14:336–43. Ferdinand KC, Patterson KP, Taylor C, Fergus IV, Nasser SA. Community-based approaches to prevention and management of hypertension and cardiovascular disease. J Clin Hypertens (Greenwich). 2012;14:336–43.
8.
go back to reference O’Loughlin J, Masson P, Dery V, Fagnan D. The role of community pharmacists in health education and disease prevention: a survey of their interests and needs in relation to cardiovascular disease. Prev Med. 1999;28:324–31. O’Loughlin J, Masson P, Dery V, Fagnan D. The role of community pharmacists in health education and disease prevention: a survey of their interests and needs in relation to cardiovascular disease. Prev Med. 1999;28:324–31.
10.
go back to reference Machado M, Bajcar J, Guzzo GC, Einarson TR. Sensitivity of patient outcomes to pharmacist interventions. Part II: systematic review and meta-analysis in hypertension management. Ann Pharmacother. 2007;41(11):1770–81. Machado M, Bajcar J, Guzzo GC, Einarson TR. Sensitivity of patient outcomes to pharmacist interventions. Part II: systematic review and meta-analysis in hypertension management. Ann Pharmacother. 2007;41(11):1770–81.
11.
go back to reference Blenkinsopp A, Anderson C, Armstrong M. Systematic review of the effectiveness of community pharmacy-based interventions to reduce risk behaviours and risk factors for coronary heart disease. J Public Health. 2003;25(2):144–53. Blenkinsopp A, Anderson C, Armstrong M. Systematic review of the effectiveness of community pharmacy-based interventions to reduce risk behaviours and risk factors for coronary heart disease. J Public Health. 2003;25(2):144–53.
12.
go back to reference Morgado M, Rolo S, Castelo-Branco M. Pharmacist intervention program to enhance hypertension control: a randomised controlled trial. Int J Clin Pharm. 2011;33(1):132–40. Morgado M, Rolo S, Castelo-Branco M. Pharmacist intervention program to enhance hypertension control: a randomised controlled trial. Int J Clin Pharm. 2011;33(1):132–40.
13.
go back to reference George J, McNamara GJ, Stewart K. The roles of community pharmacists in cardiovascular disease prevention and management. AMJ. 2011;4(5):266–72. George J, McNamara GJ, Stewart K. The roles of community pharmacists in cardiovascular disease prevention and management. AMJ. 2011;4(5):266–72.
14.
go back to reference Santschi VS, Colosimo AL, Chilero A, Burnand B, Paradis G. Pharmacists interventions to improve cardiovascular risk factors in diabetes. A systematic review and meta-analysis. Diabetes Care. 2012;35:2706–17. Santschi VS, Colosimo AL, Chilero A, Burnand B, Paradis G. Pharmacists interventions to improve cardiovascular risk factors in diabetes. A systematic review and meta-analysis. Diabetes Care. 2012;35:2706–17.
15.
go back to reference Horgan JPM, Blenkinsopp A, McManus RJ. Evaluation of a cardiovascular disease opportunistic risk assessment pilot (Heart MOT Service) in community pharmacies. J Pub Health. 2010;32(1):110–6. Horgan JPM, Blenkinsopp A, McManus RJ. Evaluation of a cardiovascular disease opportunistic risk assessment pilot (Heart MOT Service) in community pharmacies. J Pub Health. 2010;32(1):110–6.
16.
go back to reference Jahangard-Rafsanjani Z, Hakimzadeh N, Sarayani A, et al. A community pharmacy-based cardiovascular risk screening service implemented in Iran. Pharm Pract (Granada). 2017;15(2):919. Jahangard-Rafsanjani Z, Hakimzadeh N, Sarayani A, et al. A community pharmacy-based cardiovascular risk screening service implemented in Iran. Pharm Pract (Granada). 2017;15(2):919.
18.
go back to reference Osuji CU, Onwubuya EI, Ahaneku GI, Omejua EG. Pattern of cardiovascular admissions at the Nnamdi Azikiwe University Teaching Hospital, Nnewi South East Nigeria. Pan Afr Med J. 2014;17:116. Osuji CU, Onwubuya EI, Ahaneku GI, Omejua EG. Pattern of cardiovascular admissions at the Nnamdi Azikiwe University Teaching Hospital, Nnewi South East Nigeria. Pan Afr Med J. 2014;17:116.
19.
go back to reference Oguanobi NI, Ejim EC, Onwubere BJ, Ike SO, Anisiuba BC, Ikeh VO, Aneke EO. Pattern of cardiovascular disease amongst medical admissions in a regional teaching hospital in South-eastern Nigeria. Nig J Cardiol. 2013;10:77–80. Oguanobi NI, Ejim EC, Onwubere BJ, Ike SO, Anisiuba BC, Ikeh VO, Aneke EO. Pattern of cardiovascular disease amongst medical admissions in a regional teaching hospital in South-eastern Nigeria. Nig J Cardiol. 2013;10:77–80.
20.
go back to reference Hadiza S. Cardiovascular disease admissions in medical wards of a tertiary hospital in north-west Nigeria. IOSR J Dent Med Sci. 2018;17(5):47–50. Hadiza S. Cardiovascular disease admissions in medical wards of a tertiary hospital in north-west Nigeria. IOSR J Dent Med Sci. 2018;17(5):47–50.
23.
go back to reference Amadi CE, Lawal FO, Mbakwem AC, Ajuluchukwu JN, Oke DA. Knowledge of cardiovascular disease risk factors and practice of primary prevention of cardiovascular disease by Community Pharmacists in Nigeria: a cross-sectional study. Int J Clin Pharm. 2018;40(6):1587–95. Amadi CE, Lawal FO, Mbakwem AC, Ajuluchukwu JN, Oke DA. Knowledge of cardiovascular disease risk factors and practice of primary prevention of cardiovascular disease by Community Pharmacists in Nigeria: a cross-sectional study. Int J Clin Pharm. 2018;40(6):1587–95.
24.
go back to reference Rolland-Cachera MF, Sempe M, Guilloud-Bataille M, Patois E, et al. Adiposity Indices in children. Am J Clin Nutr. 1982;36:178–84. Rolland-Cachera MF, Sempe M, Guilloud-Bataille M, Patois E, et al. Adiposity Indices in children. Am J Clin Nutr. 1982;36:178–84.
25.
go back to reference National Cholesterol Education Program (NCEP): Expert Panel on Detection and Treatment of High Blood Cholesterol in Adults. Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 2002 106; 3143–3421. National Cholesterol Education Program (NCEP): Expert Panel on Detection and Treatment of High Blood Cholesterol in Adults. Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 2002 106; 3143–3421.
26.
go back to reference Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2018;138:e484–594. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2018;138:e484–594.
28.
go back to reference Reiner Z, Catapano AL, De Backer G, Graham I, Tasknen MR, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32:1769–818. Reiner Z, Catapano AL, De Backer G, Graham I, Tasknen MR, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32:1769–818.
30.
go back to reference Bovet P, Hirsiger P, Emery F, De Bernardini J, Rossier C, Trebeljahr J, Hagon-Traub I. Impact and cost of a 2-week community-based screening and awareness program for diabetes and cardiovascular risk factors in a Swiss canton. Diabetes Metab Syndr Obes. 2011;4:213–23. https://doi.org/10.2147/DMSO.S20649.CrossRef Bovet P, Hirsiger P, Emery F, De Bernardini J, Rossier C, Trebeljahr J, Hagon-Traub I. Impact and cost of a 2-week community-based screening and awareness program for diabetes and cardiovascular risk factors in a Swiss canton. Diabetes Metab Syndr Obes. 2011;4:213–23. https://​doi.​org/​10.​2147/​DMSO.​S20649.CrossRef
31.
go back to reference Carter M, Karwalajtys T, Chambers L, Kaczorowski J, Dolovich L, Gierman T, et al. Implementing a standardized community-based cardiovascular risk assessment program in 20 Ontario communities. Health Promot Int. 2009;24(4):325–33. Carter M, Karwalajtys T, Chambers L, Kaczorowski J, Dolovich L, Gierman T, et al. Implementing a standardized community-based cardiovascular risk assessment program in 20 Ontario communities. Health Promot Int. 2009;24(4):325–33.
32.
go back to reference Chiazor EI, Evans M, van Worden H, Oparah AC. A systematic review of community pharmacists’ interventions in reducing major risk factors for cardiovascular disease. J Value Health Reg Issue. 2015;7c:9–21. Chiazor EI, Evans M, van Worden H, Oparah AC. A systematic review of community pharmacists’ interventions in reducing major risk factors for cardiovascular disease. J Value Health Reg Issue. 2015;7c:9–21.
33.
go back to reference George J, McNamara K, Stewart K. The roles of community pharmacists in cardiovascular disease prevention and management. Aust Med J. 2011;4(5):266–72. George J, McNamara K, Stewart K. The roles of community pharmacists in cardiovascular disease prevention and management. Aust Med J. 2011;4(5):266–72.
34.
go back to reference Mangum SA, Kraenow KR, Narducci WA. Identifying at-risk patients through community pharmacy-based hypertension and stroke prevention screening projects. J Am Pharm Assoc (Wash). 2003;43(1):50–5. Mangum SA, Kraenow KR, Narducci WA. Identifying at-risk patients through community pharmacy-based hypertension and stroke prevention screening projects. J Am Pharm Assoc (Wash). 2003;43(1):50–5.
35.
go back to reference Onyemelukwe GC, Ogunfowokan O, Mbakwem A, Alao AK, Soroh K, Omorodion O, Abreu P. Cardiovascular risk factors in adult general out-patient clinics in Nigeria: a country analysis of the Africa and Middle East Cardiovascular Epidemiological (ACE) study. Afr Health Sci. 2017;17(4):1070–81. Onyemelukwe GC, Ogunfowokan O, Mbakwem A, Alao AK, Soroh K, Omorodion O, Abreu P. Cardiovascular risk factors in adult general out-patient clinics in Nigeria: a country analysis of the Africa and Middle East Cardiovascular Epidemiological (ACE) study. Afr Health Sci. 2017;17(4):1070–81.
37.
go back to reference Adeloye D, Basquill C, Aderemi AV, et al. An estimate of the prevalence of hypertension in Nigeria: a systematic review and meta-analysis. J Hypertens. 2015;33(2):230–42. Adeloye D, Basquill C, Aderemi AV, et al. An estimate of the prevalence of hypertension in Nigeria: a systematic review and meta-analysis. J Hypertens. 2015;33(2):230–42.
38.
go back to reference Vincent-Onabajo GO, Adaji JO, Umeonwuka CI. Prevalence of undiagnosed hypertension among traders at a regional market in Nigeria. Ann Med Health Sci Res. 2017;7:97–101. Vincent-Onabajo GO, Adaji JO, Umeonwuka CI. Prevalence of undiagnosed hypertension among traders at a regional market in Nigeria. Ann Med Health Sci Res. 2017;7:97–101.
40.
go back to reference Ogbera OA, Ekpebegh C. Diabetes mellitus in Nigeria: the past, present and future. World J Diabetes. 2014;5(6):905–11. Ogbera OA, Ekpebegh C. Diabetes mellitus in Nigeria: the past, present and future. World J Diabetes. 2014;5(6):905–11.
41.
go back to reference Uloko AE, Musa BM, Ramalan MA, Gezewa ID, Puepet FH, Uloko AT, et al. Prevalence and risk factors for diabetes mellitus in Nigeria: a systematic review and meta-analysis. Diabetes Ther. 2018;9(3):1307–16. Uloko AE, Musa BM, Ramalan MA, Gezewa ID, Puepet FH, Uloko AT, et al. Prevalence and risk factors for diabetes mellitus in Nigeria: a systematic review and meta-analysis. Diabetes Ther. 2018;9(3):1307–16.
42.
go back to reference Akarolo-Anthony SN, Willett WC, Spigelman D, Adebamowo CA. Obesity epidemic has emerged among Nigerians. BMC Pub Health. 2014;14:455. Akarolo-Anthony SN, Willett WC, Spigelman D, Adebamowo CA. Obesity epidemic has emerged among Nigerians. BMC Pub Health. 2014;14:455.
45.
go back to reference Mancia G, Bombelli M, Corrao G, Facchetti R, Madotto F, et al. Metabolic syndrome in the PAMELA study: daily life blood pressure, cardiac damage, and prognosis. Hypertension. 2007;49:40–7. Mancia G, Bombelli M, Corrao G, Facchetti R, Madotto F, et al. Metabolic syndrome in the PAMELA study: daily life blood pressure, cardiac damage, and prognosis. Hypertension. 2007;49:40–7.
46.
go back to reference Cohen HW, Hailpern SM, Alderman MH. Glucose–cholesterol interaction magnifies coronary heart disease for hypertensive patients. Hypertension. 2004;43:983–7. Cohen HW, Hailpern SM, Alderman MH. Glucose–cholesterol interaction magnifies coronary heart disease for hypertensive patients. Hypertension. 2004;43:983–7.
47.
go back to reference Mancia G, Parati G, Borghi C, Ghironzi G, et al. Smooth investigators. Hypertension prevalence, awareness, control and association with metabolic abnormalities in San Maniano population the SMOOTH Study. J Hypertens. 2006;24:837–43. Mancia G, Parati G, Borghi C, Ghironzi G, et al. Smooth investigators. Hypertension prevalence, awareness, control and association with metabolic abnormalities in San Maniano population the SMOOTH Study. J Hypertens. 2006;24:837–43.
48.
go back to reference Jahangard-Rafsanjani Z, Sarayani A, Javadi M, Hadjibabaie M, Rashidian A, Ahmadvand A, Gholami K. Pharmacists’ attitudes and perceived barriers about community pharmacy-based cardiovascular risk screening services. J Pharm Care. 2014;2(4):142–8. Jahangard-Rafsanjani Z, Sarayani A, Javadi M, Hadjibabaie M, Rashidian A, Ahmadvand A, Gholami K. Pharmacists’ attitudes and perceived barriers about community pharmacy-based cardiovascular risk screening services. J Pharm Care. 2014;2(4):142–8.
49.
go back to reference Azami Aghdash S, Ghojazadeh M, Shams-Vahdati S, Piri R, Klvany Kh, Yaghoubi R, Asli Z, Naghavi-Behzad M. Barriers and strategies for identifying and managing risk factors of cardiovascular diseases in levels of preventing, screening, and treating. J Anal Res Clin Med. 2015;3(4):197–205. Azami Aghdash S, Ghojazadeh M, Shams-Vahdati S, Piri R, Klvany Kh, Yaghoubi R, Asli Z, Naghavi-Behzad M. Barriers and strategies for identifying and managing risk factors of cardiovascular diseases in levels of preventing, screening, and treating. J Anal Res Clin Med. 2015;3(4):197–205.
50.
go back to reference Holland RW, Nimmo CM. Transitions in pharmacy practice, part 3: effecting change–the three-ring circus. Am J Health Syst Pharm. 1999;56:2235–41. Holland RW, Nimmo CM. Transitions in pharmacy practice, part 3: effecting change–the three-ring circus. Am J Health Syst Pharm. 1999;56:2235–41.
51.
go back to reference Anderson C. Health Promotion in community pharmacy: the UK situation. Patient Educ Couns. 2000;39:285–91. Anderson C. Health Promotion in community pharmacy: the UK situation. Patient Educ Couns. 2000;39:285–91.
52.
go back to reference Hindi AMK, Schafheutle EI, Jacobs S. Patient and public perspectives of community pharmacies in the United Kingdom: a systematic review. Health Expect. 2018;21:409–28. Hindi AMK, Schafheutle EI, Jacobs S. Patient and public perspectives of community pharmacies in the United Kingdom: a systematic review. Health Expect. 2018;21:409–28.
53.
go back to reference Taylor J, Krska J, Mackridge A. A community pharmacy-based cardiovascular screening service: views of service users and the public. Int J Pharm Pract. 2012;20:277–84. Taylor J, Krska J, Mackridge A. A community pharmacy-based cardiovascular screening service: views of service users and the public. Int J Pharm Pract. 2012;20:277–84.
54.
go back to reference Ogunbayo OJ, Schafheutle EI, Cutts C, Noyce PR. Self-care of long-term conditions: patients’ perspectives and their (limited) use of community pharmacies. Int J Clin Pharm. 2017;39:433–42. Ogunbayo OJ, Schafheutle EI, Cutts C, Noyce PR. Self-care of long-term conditions: patients’ perspectives and their (limited) use of community pharmacies. Int J Clin Pharm. 2017;39:433–42.
55.
go back to reference Fakih S, Marriott JL, Boardman H, Anderson C, Hussainy SY. Comparing women pharmacy consumers’ experiences with weight loss treatment in Victoria and Nottingham: a cross-sectional study. BMC Public Health. 2014;14:662. Fakih S, Marriott JL, Boardman H, Anderson C, Hussainy SY. Comparing women pharmacy consumers’ experiences with weight loss treatment in Victoria and Nottingham: a cross-sectional study. BMC Public Health. 2014;14:662.
Metadata
Title
Opportunistic screening of cardiovascular disease risk factors in community pharmacies in Nigeria: a cross-sectional study
Authors
Casmir Amadi
Folasade Lawal
Wale Ajiboye
Rosarii Agbim
Amam Mbakwem
Jayne Ajuluchukwu
David A. Oke
Publication date
01-12-2020
Publisher
Springer International Publishing
Published in
International Journal of Clinical Pharmacy / Issue 6/2020
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-020-01112-2

Other articles of this Issue 6/2020

International Journal of Clinical Pharmacy 6/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.